The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
2022 · Leukemia · 3,654 citations
https://doi.org/10.1038/s41375-022-01613-1
A
Andreas Hochhaus
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.6K
Papers
89.8K
Citations
127
h-index
676
i10-index
Andreas Hochhaus is an academic researcher from Jena University Hospital. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Chronic Lymphocytic Leukemia Research & Eosinophilic Disorders and Syndromes. The author has an h-index of 127, co-authored 1395 publications.
ORCID: 0000-0003-0626-0834Papers by this author
worksThe 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
2022 · Leukemia · 3,466 citations
https://doi.org/10.1038/s41375-022-01620-2
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
2020 · Leukemia · 1,470 citations
https://doi.org/10.1038/s41375-020-0776-2
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
2015 · Leukemia · 336 citations
https://doi.org/10.1038/leu.2015.29
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
2017 · Leukemia · 320 citations
https://doi.org/10.1038/leu.2017.253
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
2018 · Nature Medicine · 284 citations
https://doi.org/10.1038/nm.4484
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat